The Debatable Role of HIPEC in Ovarian Cancer
- PMID: 35254576
- DOI: 10.1245/s10434-022-11431-5
The Debatable Role of HIPEC in Ovarian Cancer
Comment in
-
Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.Ann Surg Oncol. 2022 May;29(5):3361-3362. doi: 10.1245/s10434-022-11501-8. Epub 2022 Mar 7. Ann Surg Oncol. 2022. PMID: 35254577 No abstract available.
Comment on
-
Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. Ann Surg Oncol. 2022. PMID: 34812982 Clinical Trial.
References
-
- Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A Phase 3 clinical trial. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-11087-7 . - DOI - PubMed
-
- Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114–25. https://doi.org/10.1016/j.ejca.2020.02.020 . - DOI - PubMed
-
- Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657–64. https://doi.org/10.1136/ijgc-2020-001640 . - DOI - PubMed
-
- Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. 2018;29(8):1610–3. https://doi.org/10.1093/annonc/mdy198 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
